Development of AX-5006 a Small Molecule Inhibitor of CsgA Aggregation As a Potential Disease Modifying Treatment for Parkinson’s Disease

Time: 12:30 pm
day: Conference Day 1 Track A AM 1


  • Understanding the role of the microbiome in Parkinson’s Disease
  • Outlining the rationale for targeting CsgA as a therapeutic for Parkinson’s Disease
  • Revealing the preclinical efficacy, pharmacokinetics, and tolerability profile of AX-5006